Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1990 Feb;53(2):102–105. doi: 10.1136/jnnp.53.2.102

Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.

R J Coleman 1, N P Quinn 1, M Traub 1, C D Marsden 1
PMCID: PMC487944  PMID: 1968963

Abstract

(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) is a new dopamine agonist which is capable of producing a sustained response in parkinsonian patients with "on-off" fluctuations when given as a continuous infusion either nasogastrically or intravenously. These data suggest that a sustained release formulation of PHNO may provide a significant, new treatment for patients with "on-off" fluctuations.

Full text

PDF
102

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cedarbaum J. M., Breck L., Kutt H., McDowell F. H. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease. Neurology. 1987 Feb;37(2):233–241. doi: 10.1212/wnl.37.2.233. [DOI] [PubMed] [Google Scholar]
  2. Cedarbaum J. M., Breck L., Kutt H., McDowell F. H. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease. Neurology. 1987 Oct;37(10):1607–1612. doi: 10.1212/wnl.37.10.1607-a. [DOI] [PubMed] [Google Scholar]
  3. Coleman R. J., Lange K. W., Quinn N. P., Loper A. E., Bondi J. V., Hichens M., Stahl S. M., Marsden C. D. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Mov Disord. 1989;4(2):129–138. doi: 10.1002/mds.870040204. [DOI] [PubMed] [Google Scholar]
  4. Coleman R. J., Temlett J. A., Quinn N. P., Stahl S. M., Marsden C. D. A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations. Clin Neuropharmacol. 1989 Feb;12(1):37–45. doi: 10.1097/00002826-198902000-00005. [DOI] [PubMed] [Google Scholar]
  5. Grandas F., Quinn N., Critchley P., Rohan A., Marsden C. D., Stahl S. M. Antiparkinsonian activity of a single oral dose of PHNO. Mov Disord. 1987;2(1):47–51. doi: 10.1002/mds.870020106. [DOI] [PubMed] [Google Scholar]
  6. Hardie R. J., Lees A. J., Stern G. M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984 Jun;107(Pt 2):487–506. doi: 10.1093/brain/107.2.487. [DOI] [PubMed] [Google Scholar]
  7. Juncos J. L., Fabbrini G., Mouradian M. M., Serrati C., Kask A. M., Chase T. N. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1987 Feb;50(2):194–198. doi: 10.1136/jnnp.50.2.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lieberman A., Chin L., Baumann G. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease. Clin Neuropharmacol. 1988 Jun;11(3):191–200. doi: 10.1097/00002826-198806000-00001. [DOI] [PubMed] [Google Scholar]
  9. Martin G. E., Williams M., Pettibone D. J., Yarbrough G. G., Clineschmidt B. V., Jones J. H. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. J Pharmacol Exp Ther. 1984 Sep;230(3):569–576. [PubMed] [Google Scholar]
  10. Nutt J. G., Woodward W. R., Hammerstad J. P., Carter J. H., Anderson J. L. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med. 1984 Feb 23;310(8):483–488. doi: 10.1056/NEJM198402233100802. [DOI] [PubMed] [Google Scholar]
  11. Obeso J. A., Luquin M. R., Martínez-Lage J. M. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet. 1986 Mar 1;1(8479):467–470. doi: 10.1016/s0140-6736(86)92929-6. [DOI] [PubMed] [Google Scholar]
  12. Rupniak N. M., Tye S. J., Jennings C. A., Loper A. E., Bondi J. V., Hichens M., Hand E., Iversen S. D., Stahl S. M. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology. 1989 Mar;39(3):329–335. doi: 10.1212/wnl.39.3.329. [DOI] [PubMed] [Google Scholar]
  13. Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES